


Fish oil to improve school performance and delay cognitive decline: how strong is the evidence of benefit?




Dr Alan Dangour
Registered Public Health Nutritionist
Nutrition and Public Health Intervention Research Unit
London School of Hygiene & Tropical Medicine



Mechanisms?

- Brain is 22-24% lipid, high concentrations of n-3 LCPs (DHA) in brain and retinal phospholipids
- Clear need for DHA *in utero* (and first 2 years) for optimal brain and retinal development
- DHA effects gene expression, neurogenesis, membrane structure and function, protein lipid interactions and receptor binding
- Very new data (Innis 2007) suggest effect on release of neurotransmitters which may have potential impact on mood/behaviour of children

Action of DHA on neuronal synapse



- DHA modulates neurotransmitter release at nerve synapse via actions on SNARE proteins
- Changes in SNARE protein function may be linked to behaviour/learning

University of Teesside review of fish oil trials and childhood performance

- Findings were mixed and therefore inconclusive
- Only the Durham trial reported consistent improvements in both objective and subjective behavioural and educational outcomes
- Caution when translating evidence of effect from children with neurodevelopmental disorders to mainstream school children
- Dosages in supplements given in trials are unlikely to be achieved through diet alone
- Further large scale trials needed

(Summerbell, in press)

NEMO Study

Nutrition Enhancement for Mental Optimisation

- 396 children 6-10yr in Australia (well nourished)
- 384 children in Indonesia (marginally nourished)
- RCT testing effect of multinutrients (Fe, Zn, A, folate, B₆, B₁₂, C), fish oil (110mg/d), both or neither for 12 months on learning and memory
- Blood nutrient profiles improved over 12 months
- Fish oil – no effect on learning outcomes
- Multinutrients – small effect on learning and memory, no effect on intelligence and attention

(NEMO Study group, AJCN, 2007)

Summary of childhood data


- Some potential mechanisms of effect
- Inconclusive evidence of effect of fish oil on ability and behaviour among school-age children from RCTs
- Small RCTs mostly limited to children with neurodevelopmental disorders
- Issue of importance for public health
- Large RCTs urgently needed



(Lucas Cranach the Elder, 1546)

Global prevalence of dementia: a Delphi consensus study

Olus P Ferri, Martin Prince, Carol Brayne, Henry Brodaty, Laura Fratiglioni, Mary Ganguli, Kathleen Hall, Kazuo Hasegawa, Hugh Hendrie, Yueqin Huang, Anthony Jam, Colin Mathar, Paulo R Menezes, Elizabeth Rimmer, Marcia Sczufca, for Alzheimer's Disease International




- 24.3 million today
- 4.6 million new cases every year
- 81.1 million 2040
- 100% increase in developed countries
- 300% increase in India and China

(Ferri, Lancet, 2005)


Dementia in the UK

- 700,000 cases today – 1 in every 88 people
- 940,000 by 2021 – 1 in every 71 people
- 1,735,000 by 2051



(Alzheimer's Society, 2007)

Systematic reviews and meta-analysis



Mechanisms?

- DHA metabolised to *neuroprotectin D1*
- DHA regulates gene expression
- Combined with EPA, actions may:
 - improve vascular integrity
 - reduce microthrombotic obstruction
 - enhance neuronal health and signalling

Role of diet?

- Goodwin (JAMA, 1983)
 - 260 community living adults 60+ years
 - low blood levels of vitamin C and B₁₂ associated with worse cognitive function
- Numerous surveys show associations between nutrients and cognitive function

Systematic review of evidence on fish oil and cognitive function

- Inclusion criteria
 - Human
 - RCT, cohort or case-control
 - describe effect of fish oil on cognitive function, or incidence/treatment of dementia
- 5,865 citations
 - 5 relevant (4 cohort studies, 1 RCT)

(Issa, Dement Geriatr Cogn Disord, 2006)

Review conclusions

In four [cohort] studies that assessed the effects of n-3 LCPs on incidence and treatment of dementia, a trend in favour of n-3 LCPs (fish and total n-3 consumption) toward reducing risk of dementia and improving cognitive function was reported.

- One RCT included in the review was small and of poor quality

(Issa, Dement Geriatr Cogn Disord, 2006)


Fish intake and dementia

Fish consumption	n	Cases	Incidence/100 py
Once a day	19	1	1.00 (0.00-2.97)
At least once/wk	1122	124	2.05 (1.69-2.41)
Sometimes	240	35	2.90 (1.94-3.87)
Never	35	10	6.61 (2.51-10.70)

- 1674 free-living French people aged ≥ 68 years
- Follow-up period - 7 years
- Hazard ratio of at least once/wk vs. less = 0.66 (0.47-0.93)


(Barberger-Gateau, BMJ, 2002)

Plasma DHA and dementia



Omega 3 fatty acid for the prevention of dementia (Review)

Lim WS, Gammack JK, Van Niekerk J, Dangour AD



**THE COCHRANE
COLLABORATION®**

The Cochrane Database of Systematic Reviews 2006 Issue 2

Cochrane conclusions

There is a growing body of evidence from biological, observational and epidemiological studies that suggests a protective effect of n-3 LCPs against dementia. However, until data from randomized trials become available for analysis, there is no good evidence to support the use of dietary or supplemental n-3 LCPs for the prevention of cognitive impairment or dementia.

ORIGINAL CONTRIBUTION

ω -3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegaAD Study


A Randomized Double-blind Trial

Yvonne Freund-Levi, MD; Maria Eriksson-Jonhagen, MD, PhD; Tommy Cedersholm, MD, PhD; Hans Basan, MD, PhD; Gerd Faxälv-Ingving, PhD; Anita Garlind, MD, PhD; Inger Vedin, MSc; Bengt Vessby, MD, PhD; Lars-Olof Wahlund, MD, PhD; Jan Palmblad, MD, PhD

- 174 people aged 74 years with Alzheimer's disease and MMSE > 15
- RCT of either 1.7g DHA + 0.6g EPA or placebo
- Primary outcome – change in Mini Mental State Examination (MMSE) Score

(Freund-Levi, Arch Neurol, 2006)

	MMSE score (0-30)	
	Baseline	6 months
All subjects (n=174)		
Fish oil	23.6	22.8
Placebo	23.2	22.4
MMSE >27 points (n=32)		
Fish oil	28.4	27.9
Placebo	28.5	26.0



(Freund-Levi, Arch Neurol, 2006)

MEMO study

Mental health in Elderly Maintained with Omega-3

- n=302; 65+ years; MMSE > 21
- Randomised for 6 months to:
 - 0.4g n-3 LCPs
 - 2g n-3 LCPs
 - placebo
- Primary outcome: cognitive function and mental well-being

(van der Rest, submitted)

Summary of older people data

- Good mechanistic evidence of potential effect
- Some evidence from surveys
- Good evidence from cohort studies
- No evidence of effect from RCTs
- Large RCTs urgently needed

Why don't trials "work"?

- Residual confounding in cohort studies
- Existing trials are too small or short
- Supplement dose too low
- Outcome measures not sensitive
- Baseline status
- ApoE (other gene) status



Older
People
And n-3
Long-chain
polyunsaturated
fatty acids study



FOOD
STANDARDS
AGENCY

MRC
General Practice
Research
Framework



Hypotheses

- Daily supplementation for 24 months with 0.7g n-3 LCPs (0.5g DHA + 0.2g EPA) will slow cognitive decline in older people
- Daily supplementation for 24 months with 0.7g n-3 LCPs will benefit eye health in older people

N.B. 0.7g = 2 portions of oily fish / week



Study design

- Double-blind placebo-controlled RCT
- 868 cognitively healthy adults 70-79y drawn from 20 GP practices in UK
- Daily capsules for 24 months
- Cognitive function tests at 0 and 24 months
- Retinal function tests on sub-sample
- Results due – Autumn 2008
- www.opal-study.org.uk

Conclusions

- Currently no good quality evidence from RCTs to support the use of fish oil supplements to enhance academic or behavioural performance in school-age children
- Currently no good quality evidence from RCTs to support the use of fish oil supplements to slow or prevent cognitive decline in older people
- Active area of research

Final word

... this should not discourage further research on the relationship between nutrition and cognitive function, [but] it does underscore the critical importance of rigorous experimental design if such studies are to be meaningfully interpreted, and it suggests that nutritional supplementation cannot yet be viewed as a demonstrably effective therapy for cognitive problems in the elderly.

(Raskind, JAMA, 1983)